Skip to main content
Explore URMC

menu

Prostate Cancer: A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)

Research Question:
Is rucaparib is a good treatment option in patients with prostate cancer, and who have mutations in BRCA, ATM, or other DNA-repair genes that are linked with benefit from treatment with a PARP inhibitor?

Basic Study Information

Purpose:
This research study is divided into three phases: Screening Phase is performed to find out if you are eligible for the study. If you qualify, you will be enrolled into the study and begin treatment. Treatment Phase (continuous dosing with rucaparib) Follow-up Phase: Follow Up visit (28 days after your last dose of rucaparib) and long term follow-up approximately every 12 weeks

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/study/NCT02952534?term=triton2&recrs=ab&rank=1&show_locs=Y#locn
Study Reference #: IGUP17014

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Guancial

Study Contact Information

Study Coordinator: Ayesha Khan
Phone: (585) 275-3351
Email: Ayesha_Khan@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Prostate Cancer

Return to Search